Management of truncal acne with oral sarecycline: pooled results from two Phase 3 clinical trials
Recommended Citation
Del Rosso JQ, Stein Gold LF, Baldwin H, Harper JC, Zeichner J, Obagi S, Graber E, Jimenez X. Management of truncal acne with oral sarecycline: pooled results from two Phase 3 clinical trials. J Clin Aesthet Dermatol 2022; 15(4 SUPPL 1):S9.
Document Type
Conference Proceeding
Publication Date
5-27-2022
Publication Title
J Clin Aesthet Dermatol
Abstract
Background: Acne vulgaris is a common skin disease that affects the face, chest, and back. While truncal acne is present in at least 50 percent of patients, clinical studies have focused predominantly on facial acne.1 , 2 Few treatments to date have been evaluated for truncal acne. Sarecycline is a narrow-spectrum, third-generation, tetracycline-class oral drug approved for the treatment of acne. Pivotal Phase 3 studies show that sarecycline is safe, well-tolerated, and effective treatment for moderate to severe acne vulgaris. Methods: Pooled analysis was performed for truncal acne results with sarecycline from the two Phase 3 studies. Investigator Global Assessment (IGA) success was evaluated at Weeks 3, 6, 9, and 12. Results: Chest IGA success rate were significantly greater with sarecycline versus placebo at Weeks 3 (11.84% vs. 7.71%, respectively; p=0.0192), 6 (18.81% vs. 14.03%, respectively; p=0.0390), and 12 (33.42% vs. 20.77%, respectively; p<0.0001). Back IGA success rate were also significantly greater with sarecycline versus placebo group at Weeks 3 (12.13% vs. 7.04%, respectively; p=0.0023), 6 (18.42% vs. 14.34%, respectively; p=0.0412), 9 (29.05% vs. 19.88%, respectively; p=0.0004) and 12 (33.07% vs. 21.91%, respectively; p<0.0001). Conclusion: Sarecycline efficacy for truncal acne was observed within three weeks after treatment, supporting sarecycline as an optimal choice for oral treatment of moderate to severe truncal acne.
Volume
15
Issue
4 SUPPL 1
First Page
S9
